Abstract
Purpose The Actionable Register of Geneva Out- and inpatients with SARS-CoV-2 (ARGOS) is an ongoing prospective cohort created by the Geneva Directorate of Health (GDH). It consists of an operational database compiling all SARS-CoV-2 test results conducted in the Geneva area since late February 2020. This article aims at presenting this comprehensive cohort, in light of some of the varying public health measures in Geneva, Switzerland, since March 2020.
Participants As of June 1st, 2021, the database included 356’868 patients, among which 65’475 had at least one positive test result for SARS-CoV-2. Among all positive patients, 37.6% were contacted only once, 10.6 % had one follow-up call, 8.5% had two, and 27.7% had 3 or more follow-up calls. Participation rate among positive patients is 94%. Data collection is ongoing.
Findings to date ARGOS data illustrates the magnitude of COVID-19 pandemic in Geneva, Switzerland, and details a variety of population factors and outcomes. The content of the cohort includes demographic data, comorbidities and risk factors for poor clinical outcome, self-reported COVID-19 symptoms, environmental and socio-economic factors, prospective and retrospective contact tracing data, travel quarantine data, and deaths. The registry has already been used in several publications focusing on symptoms and long COVID, infection fatality rate, and re-infection.
Future plans The data of this large real-world registry provides a valuable resource for various types of research, such as clinical research, epidemiological research or policy assessment as it illustrates the impact of public health policies and overall disease burden of COVID-19.
STRENGTHS AND LIMITATIONS OF THIS STUDY
ARGOS’ main strength consists of its large number of cases, representative of all diagnosed cases on a regional level with the primary aim of assessing all cases.
ARGOS involves every individual who performed a SARS-CoV-2 test (PCR or antigenic) and is not limited to hospitalized patients, thus providing a valuable resource to assess the overall disease burden of COVID-19 in a geographically defined population.
To mitigate confounding effects and improve data analysis and interpretation, we present the data according to four policy periods.
This cohort is multicentric as it includes all tests performed in Geneva’s hospitals (both public and private), private practices and medical centers.
Due to operational needs, symptoms and comorbidities are self-reported, which may lead to measurement error or misclassification.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ARGOS is supported by Geneva State public funds and by a grant from The Swiss National Science Foundation LIVES, project #2020-01273.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The register is administered by a committee of co-Principal Investigators belonging to the GDH and HUG, with the agreement of the cantonal ethic committee (CCER protocol 2020-01273)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The numbers concerning our cohort have been updated, and several new aspects have been added, including: -Contact tracing information -Quarantine (contact with positive cases and travelers) information -COVID19 related Deaths -Context of infection -Symptoms
Data Availability
Deidentified ARGOS data can be available upon reasonable request, including a research protocol, using the form https://edc.hcuge.ch/surveys/?s=TLT9EHE93C.
